Safety Considerations with Gastrointestinally Active Lipid-Lowering Drugs

This publication has 49 references indexed in Scilit:

• Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force
  The American Journal of Cardiology, 2006
• Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin)
  The American Journal of Cardiology, 2006
• Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study
  American Heart Journal, 2005
• Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin
  American Heart Journal, 2004
• Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals
  The American Journal of Cardiology, 2004
• Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
  The American Journal of Cardiology, 2004
• The liver and lovastatin
  The American Journal of Cardiology, 2002
• Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent
  Expert Opinion on Investigational Drugs, 2000
• Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia
  The Journal of Pediatrics, 1996
• The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients
  Atherosclerosis, 1995